HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Association Between Wearable Device-Based Measures of Physical Frailty and Major Adverse Events Following Lower Extremity Revascularization.

AbstractImportance:
Physical frailty is a key risk factor associated with higher rates of major adverse events (MAEs) after surgery. Assessing physical frailty is often challenging among patients with chronic limb-threatening ischemia (CLTI) who are often unable to perform gait-based assessments because of the presence of plantar wounds.
Objective:
To test a frailty meter (FM) that does not rely on gait to determine the risk of occurrence of MAEs after revascularization for patients with CLTI.
Design, Setting, and Participants:
This cohort study included 184 consecutively recruited patients with CLTI at 2 tertiary care centers. After 32 individuals were excluded, 152 participants were included in the study. Data collection was conducted between May 2018 and June 2019.
Exposures:
Physical frailty measurement within 1 week before limb revascularization and incidence of MAEs for as long as 1 month after surgery.
Main Outcomes and Measures:
The FM works by quantifying weakness, slowness, rigidity, and exhaustion during a 20-second repetitive elbow flexion-extension exercise using a wrist-worn sensor. The FM generates a frailty index (FI) ranging from 0 to 1; higher values indicate progressively greater severity of physical frailty.
Results:
Of 152 eligible participants (mean [SD] age, 67.0 [11.8] years; 59 [38.8%] women), 119 (78.2%) were unable to perform the gait test, while all could perform the FM test. Overall, 53 (34.9%), 58 (38.1%), and 41 (27.0%) were classified as robust (FI <0.20), prefrail (FI ≥0.20 to <0.35), or frail (FI ≥0.35), respectively. Within 30 days after surgery, 24 (15.7%) developed MAEs, either major adverse cardiovascular events (MACE; 8 [5.2%]) or major adverse limb events (MALE; 16 [10.5%]). Baseline demographic characteristics were not significantly different between frailty groups. In contrast, the FI was approximately 30% higher in the group that developed MAEs (mean [SD] score, 0.36 [0.14]) than those who were MAE free (mean [SD] score, 0.26 [0.13]; P = .001), with observed MAE rates of 4 patients (7.5%), 7 patients (12.1%), and 13 patients (31.7%) in the robust, prefrail and frail groups, respectively (P = .004). The FI distinguished individuals who developed MACE and MALE from those who were MAE free (MACE: mean [SD] FI score, 0.38 [0.16]; P = .03; MALE: mean [SD] FI score, 0.35 [0.13]; P = .004) after adjusting by body mass index.
Conclusions and Relevance:
In this cohort study, measuring physical frailty using a wrist-worn sensor during a short upper extremity test was a practical method for stratifying the risk of MAEs following revascularization for CLTI when the administration of gait-based tests is often challenging.
AuthorsBijan Najafi, Narek Veranyan, Alejandro Zulbaran-Rojas, Catherine Park, Hung Nguyen, Quinn Kaleikaumaka Nakahara, Hector Elizondo-Adamchik, Jayer Chung, Joseph L Mills, Miguel Montero-Baker, David G Armstrong, Vincent Rowe
JournalJAMA network open (JAMA Netw Open) Vol. 3 Issue 11 Pg. e2020161 (11 02 2020) ISSN: 2574-3805 [Electronic] United States
PMID33211104 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Topics
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Female
  • Frail Elderly (statistics & numerical data)
  • Frailty (diagnosis)
  • Geriatric Assessment (methods, statistics & numerical data)
  • Humans
  • Lower Extremity (surgery)
  • Male
  • Middle Aged
  • Monitoring, Physiologic (instrumentation, statistics & numerical data)
  • United States
  • Vascular Surgical Procedures (adverse effects)
  • Wearable Electronic Devices (statistics & numerical data)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: